Medical therapy of secondary hyperparathyroidism in chronic kidney disease: old and new drugs

Bibliography

• DE FRANCISCO AL: Secondary hyperparathyroidism: review of the disease and its treatment. Clin. Ther. (2004) 26(12):1976-1993.
   PubMedGoogle Scholar
• GANESH SK, STACK AG, LEVIN NW, HULBERT-SHEARON T, PORT FK: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. (2001) 12(10):2131-2138.
   PubMed Web of Science ®Google Scholar
• BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. (1998) 31(4):607-617.
   PubMed Web of Science ®Google Scholar
• BLOCK GA, KLASSEN PS, LAZARUS JM et al.: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. (2004) 15(8):2208-2218.
   PubMed Web of Science ®Google Scholar
• YOUNG EW, ALBERT JM, SATAYATHUM S et al.: Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. (2005) 67(3):1179-1187.
   PubMed Web of Science ®Google Scholar
• EKNOYAN G, LEVIN A, LEVIN N: Bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. (2003) 42(Suppl. 3):S1-s201.
   PubMed Web of Science ®Google Scholar
• YOUNG EW, AKIBA T, ALBERT JM et al.: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am. J. Kidney Dis. (2004) 44(5 Suppl. 3):34-38.
   PubMed Web of Science ®Google Scholar
• BROWN EM: Calcium receptor and regulation of parathyroid hormone secretion. Rev. Endocr. Metab. Disord. (2000) 1(4):307-315.
   PubMedGoogle Scholar
• BROWN EM, MACLEOD RJ: Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. (2001) 81(1):239-297.
   PubMed Web of Science ®Google Scholar
• D’SOUZA-LI L, YANG B, CANAFF L et al.: Identification and functional.characterization of novel calcium-sensing receptor mutations in familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia. J. Clin. Endocrinol. Metab. (2002) 87(3):1309-1318.
   PubMed Web of Science ®Google Scholar
• JANICIC N, PAUSOVA Z, COLE DE, HENDY GN: Insertion of an Alu sequence in the Ca(2+)-sensing receptor gene in familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Am. J. Hum. Genet. (1995) 56(4):880-886.
   PubMed Web of Science ®Google Scholar
• PEARCE SH, TRUMP D, WOODING C et al.: Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J. Clin. Invest. (1995) 96(6):2683-2692.
   PubMedGoogle Scholar
• CONLEY YP, FINEGOLD DN, PETERS DG et al.: Three novel activating mutations in the calcium-sensing receptor responsible for autosomal dominant hypocalcemia. Mol. Genet. Metab. (2000) 71(4):591-598.
   PubMedGoogle Scholar
• BROWN EM: Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J. Clin. Endocrinol. Metab. (1983) 56(3):572-581.
   PubMed Web of Science ®Google Scholar
• FELSENFELD AJ, RODRIGUEZ M, DUNLAY R, LLACH F: A comparison of parathyroid-gland function in haemodialysis patients with different forms of renal osteodystrophy. Nephrol. Dial. Transplant. (1991) 6(4):244-251.
   PubMed Web of Science ®Google Scholar
• DUSSO AS, BROWN AJ, SLATOPOLSKY E: Vitamin D. Am. J. Physiol. Renal Physiol. (2005) 289(1):F8-F28.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ M, CANALEJO A, GARFIA B, AGUILERA E, ALMADEN Y: Pathogenesis of refractory secondary hyperparathyroidism. Kidney Int. Suppl. (2002) 80:155-160.
   Google Scholar
• SLATOPOLSKY E, BROWN A, DUSSO A: Pathogenesis of secondary hyperparathyroidism. Kidney Int. Suppl. (1999) 73:S14-S19.
   PubMedGoogle Scholar
• ARNOLD A, BROWN MF, URENA P et al.: Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J. Clin. Invest. (1995) 95(5):2047-2053.
   PubMed Web of Science ®Google Scholar
• TOMINAGA Y, TANAKA Y, SATO K, NAGASAKA T, TAKAGI H: Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin. Surg. Oncol. (1997) 13(2):78-86.
   PubMed Web of Science ®Google Scholar
• MAYER GP, HABENER JF, POTTS JT Jr: Parathyroid hormone secretion in vivo. Demonstration of a calcium-independent nonsuppressible component of secretion. J. Clin. Invest. (1976) 57(3):678-683.
   PubMedGoogle Scholar
• GOGUSEV J, DUCHAMBON P, HORY B et al.: Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. (1997) 51(1):328-336.
   PubMed Web of Science ®Google Scholar
• KIFOR O, MOORE FD, JR., WANG P et al.: Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. (1996) 81(4):1598-1606.
   PubMed Web of Science ®Google Scholar
• FUKUDA N, TANAKA H, TOMINAGA Y et al.: Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J. Clin. Invest. (1993) 92(3):1436-1443.
   PubMed Web of Science ®Google Scholar
• TOKUMOTO M, TSURUYA K, FUKUDA K et al.: Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int. (2002) 62(4):1196-1207.
   PubMed Web of Science ®Google Scholar
• MARTIN LN, KAYATH MJ, VIEIRA JG, NOSE-ALBERTI V: Parathyroid glands in uraemic patients with refractory hyperparathyroidism: histopathology and p53 protein expression analysis. Histopathology (1998) 33(1):46-51.
   PubMedGoogle Scholar
• KRAUSE MW, HEDINGER CE: Pathologic study of parathyroid glands in tertiary hyperparathyroidism. Hum. Pathol. (1985) 16(8):772-784.
   PubMed Web of Science ®Google Scholar
• STEDDON SJ, CUNNINGHAM J: Calcimimetics and calcilytics-fooling the calcium receptor. Lancet (2005) 365(9478):2237-2239.
   PubMed Web of Science ®Google Scholar
• CLARKSON EM, MCDONALD SJ, DE WARDENER HE: The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin. Sci. (1966) 30(3):425-438.
   PubMed Web of Science ®Google Scholar
• MEYRIER A, MARSAC J, RICHET G: The influence of a high calcium carbonate intake on bone disease in patients undergoing hemodialysis. Kidney Int. (1973) 4(2):146-153.
   PubMed Web of Science ®Google Scholar
• GOODMAN WG, GOLDIN J, KUIZON BD et al.: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. (2000) 342(20):1478-1483.
   PubMed Web of Science ®Google Scholar
• GUERIN AP, LONDON GM, MARCHAIS SJ, METIVIER F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol. Dial. Transplant. (2000) 15(7):1014-1021.
   PubMed Web of Science ®Google Scholar
• BLOCK GA, SPIEGEL DM, EHRLICH J et al.: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. (2005) 68(4):1815-1824.
   PubMed Web of Science ®Google Scholar
• CANNATA ANDIA JB: Adynamic bone and chronic renal failure: an overview. Am. J. Med. Sci. (2000) 320(2):81-84.
   PubMedGoogle Scholar
• SLATOPOLSKY E, WEERTS C, LOPEZ-HILKER S et al.: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N. Engl. J. Med. (1986) 315(3):157-161.
   PubMed Web of Science ®Google Scholar
• MAI ML, EMMETT M, SHEIKH MS et al.: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. (1989) 36(4):690-695.
   PubMed Web of Science ®Google Scholar
• CHERTOW GM, BURKE SK, LAZARUS JM et al.: Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am. J. Kidney Dis. (1997) 29(1):66-71.
   PubMed Web of Science ®Google Scholar
• CHERTOW GM, DILLON MA, AMIN N, BURKE SK: Sevelamer with and without calcium and vitamin D: observations from a long-term open-label clinical trial. J. Ren. Nutr. (2000) 10(3):125-132.
   PubMedGoogle Scholar
• CHERTOW GM, BURKE SK, RAGGI P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. (2002) 62(1):245-252.
   PubMed Web of Science ®Google Scholar
• QUNIBI WY, HOOTKINS RE, MCDOWELL LL et al.: Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. (2004) 65(5):1914-1926.
   PubMed Web of Science ®Google Scholar
• SUKI W, ZABANEH R, CANGIANO J et al.: The DCOR trial a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. Presented at the American Society of Nephrology Renal Week. Philadelphia, PA, USA (8 – 13 November 2005) Abstract TH-PO745.
   Google Scholar
• GALLIENI M, COZZOLINO M, BRANCACCIO D: Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder. Kidney Int. (2000) 57(4):1776-1777.
   PubMed Web of Science ®Google Scholar
• D’HAESE PC, SPASOVSKI GB, SIKOLE A et al.: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. Suppl. (2003) 85:S73-S78.
   PubMedGoogle Scholar
• JOY MS, FINN WF: Randomized, double-blind, placebo-controlled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am. J. Kidney Dis. (2003) 42(1):96-107.
   PubMed Web of Science ®Google Scholar
• HUTCHISON AJ, MAES B, VANWALLEGHEM J et al.: Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin. Pract. (2005) 100(1):c8-c19.
   PubMed Web of Science ®Google Scholar
• LOCATELLI F, D’AMICO M, PONTORIERO G: Lanthanum carbonate (Shire). IDrugs (2003) 6(7):688-695.
   PubMed Web of Science ®Google Scholar
• WEBSTER I, GILL M: Lanthanum carbonate, a new phosphorus binder, is well tolerated over a 3 year period in dialysis patients. Presented at the European Renal Association – European Dialysis and Transplantation Association Annual Meeting. Lisbon, Portugal (15 – 18 May 2004) Abstract SP-268 and poster.
   Google Scholar
• SLATOPOLSKY E, LIAPIS H, FINCH J: Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int. (2005) 68(6):2809-2813.
   PubMed Web of Science ®Google Scholar
• CANAVESE C, MEREU C, NORDIO M, SABBIONI E, AIME S: Blast from the past: the aluminum’s ghost on the lanthanum salts. Curr. Med. Chem. (2005) 12(14):1631-1636.
   PubMedGoogle Scholar
• BERL T, BERNS AS, HUFER WE et al.: 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann. Intern. Med. (1978) 88(6):774-780.
   PubMedGoogle Scholar
• MEMMOS DE, EASTWOOD JB, TALNER LB et al.: Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Br. Med. J. (1981) 282(6280):1919-1924.
   PubMedGoogle Scholar
• BRANDI L, DAUGAARD H, EGSMOSE C et al.: Intermittent intravenous followed by intermittent oral 1 alpha(OH)D3 treatment of secondary hyperparathyroidism in uraemia. J. Intern. Med. (1996) 239(4):353-360.
   PubMedGoogle Scholar
• TENG M, WOLF M, LOWRIE E et al.: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. (2003) 349(5):446-456.
   PubMed Web of Science ®Google Scholar
• OWDA AK, MOUSA D, ABDALLAH AH et al.: Long-term intravenous calcitriol in secondary hyperparathyroidism: the role of technetium-99m-MIBI scintigraphy in predicting the response to treatment. Ren. Fail. (2002) 24(2):165-173.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ M, CARAVACA F, FERNANDEZ E et al.: Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Kidney Int. (1999) 56(1):306-317.
   PubMedGoogle Scholar
• MALBERTI F, CORRADI B, COSCI P et al.: Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism. Am. J. Kidney Dis. (1996) 28(5):704-712.
   PubMedGoogle Scholar
• FUKAGAWA M, KITAOKA M, YI H et al.: Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron (1994) 68(2):221-228.
   PubMed Web of Science ®Google Scholar
• SZABO A, MERKE J, BEIER E, MALL G, RITZ E: 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int. (1989) 35(4):1049-1056.
   PubMed Web of Science ®Google Scholar
• COZZOLINO M, LU Y, FINCH J, SLATOPOLSKY E, DUSSO AS: p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int. (2001) 60(6):2109-2117.
   PubMed Web of Science ®Google Scholar
• QUARLES LD, YOHAY DA, CARROLL BA et al.: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. (1994) 45(6):1710-1721.
   PubMed Web of Science ®Google Scholar
• FUKAGAWA M, OKAZAKI R, TAKANO K et al.: Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N. Engl. J. Med. (1990) 323(6):421-422.
   PubMed Web of Science ®Google Scholar
• MOE SM, DRUEKE TB: Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am. J. Nephrol. (2003) 23(6):369-379.
   PubMed Web of Science ®Google Scholar
• JONO S, NISHIZAWA Y, SHIOI A, MORII H: 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation (1998) 98(13):1302-1306.
   PubMed Web of Science ®Google Scholar
• HENLEY C, COLLOTON M, CATTLEY RC et al.: 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol. Dial. Transplant. (2005) 20(7):1370-1377.
   PubMed Web of Science ®Google Scholar
• MOE SM, O’NEILL KD, DUAN D et al.: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. (2002) 61(2):638-647.
   PubMed Web of Science ®Google Scholar
• SHALHOUB V, SHATZEN E, HENLEY C et al.: Microarray analysis implicates cytokine and wnt signalling pathways in bovine aorta smooth muscle cells that calcify in the presence of calcitriol and paricalcitol in vitro. ERA-EDTA 2005 – European Renal Association – European Dialysis and Transplantation Association. Istanbul, Turkey, 4 – 7 June (Abstract M026 and Poster) Nephrol. Dial. Transplantat. (2005) 20(Suppl. 5):V196.
   Google Scholar
• BROWN AJ, DUSSO AS, SLATOPOLSKY E: Vitamin D analogues for secondary.hyperparathyroidism. Nephrol. Dial. Transplant. (2002) 17(Suppl. 10):10-19.
   PubMed Web of Science ®Google Scholar
• DUSSO AS: Vitamin D receptor: mechanisms for vitamin D resistance in renal failure. Kidney Int. Suppl. (2003) 85:S6-S9.
   Google Scholar
• SPRAGUE SM, LLACH F, AMDAHL M, TACCETTA C, BATLLE D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. (2003) 63(4):1483-1490.
   PubMed Web of Science ®Google Scholar
• SHOJI T, SHINOHARA K, KIMOTO E et al.: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol. Dial. Transplant. (2004) 19(1):179-184.
   PubMed Web of Science ®Google Scholar
• TENG M, WOLF M, OFSTHUN MN et al.: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. (2005) 16(4):1115-1125.
   PubMed Web of Science ®Google Scholar
• DE FRANCISCO AL: Cinacalcet HCl: a novel therapeutic for hyperparathyroidism. Expert Opin. Pharmacother. (2005) 6(3):441-452.
   PubMed Web of Science ®Google Scholar
• NEMETH EF, STEFFEY ME, HAMMERLAND LG et al.: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl Acad. Sci.USA (1998) 95(7):4040-4045.
   PubMed Web of Science ®Google Scholar
• LEVI R, GABERMAN E, SILVER J, MARTIN D, NAVEH-MANY T: The calcimimetic NPS R-568 decreases PTH gene expression in rats with secondary hyperparathyroidism due to experimental uremia. ERA-EDTA 2005 – European Renal Association – European Dialysis and Transplantation Association. Istanbul, Turkey, 4 – 7 June (Abstract SP014 and Poster). Nephrol. Dial. Transplant. (2005) 20(Suppl. 5):v24.
   Google Scholar
• GOODMAN WG, HLADIK GA, TURNER SA et al.: The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J. Am. Soc. Nephrol. (2002) 13(4):1017-1024.
   PubMed Web of Science ®Google Scholar
• BROWN EM: Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro. Curr. Opin. Nephrol. Hypertens. (1993) 2(4):541-551.
   PubMedGoogle Scholar
• COLLOTON M, SHATZEN E, MILLER G et al.: Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. (2005) 67(2):467-476.
   PubMed Web of Science ®Google Scholar
• CHIN J, MILLER SC, WADA M et al.: Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J. Am. Soc. Nephrol. (2000) 11(5):903-911.
   PubMed Web of Science ®Google Scholar
• WADA M, FURUYA Y, SAKIYAMA J et al.: The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J. Clin. Invest. (1997) 100(12):2977-2983.
   PubMed Web of Science ®Google Scholar
• MIZOBUCHI M, HATAMURA I, SAJI F et al.: The linkage between the parathyroid cell proliferation and the expressions of calcium sensing and vitamin D receptor by calcimimetics in uremic rats. J. Am. Soc. Nephrol. (2003) 14:464A.
   Google Scholar
• MIZOBUCHI M, HATAMURA I, OGATA H et al.: Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J. Am. Soc. Nephrol. (2004) 15(10):2579-2587.
   PubMed Web of Science ®Google Scholar
• ALMADEN Y, RODRIGUEZ M, CANALEJO A et al.: The calcimimetic NPS R-568 increases parathyroid vitamin D receptor (VDR) mRNA expression in vitro and in vivo. ERA-EDTA 2005 – European Renal Association – European Dialysis and Transplantation Association. Istanbul, Turkey, 4 – 7 June (Abstract SP017 and Poster). Nephrol. Dial. Transplant. (2005) 20:V25.
   Google Scholar
• LINDBERG JS, MOE SM, GOODMAN WG et al.: The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. (2003) 63(1):248-254.
   PubMed Web of Science ®Google Scholar
• LINDBERG JS, CULLETON B, WONG G et al.: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J. Am. Soc. Nephrol. (2005) 16(3):800-807.
   PubMed Web of Science ®Google Scholar
• QUARLES LD, SHERRARD DJ, ADLER S et al.: The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J. Am. Soc. Nephrol. (2003) 14(3):575-583.
   PubMed Web of Science ®Google Scholar
• BLOCK GA, MARTIN KJ, DE FRANCISCO AL et al.: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. (2004) 350(15):1516-1525.
   PubMed Web of Science ®Google Scholar
• SILVERBERG SJ, BONE HG III, MARRIOTT TB et al.: Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N. Engl. J. Med. (1997) 337(21):1506-1510.
   PubMed Web of Science ®Google Scholar
• MOE SM, CHERTOW GM, COBURN JW et al.: Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. (2005) 67(2):760-771.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM J, URENA P, REICHEL H et al.: Long term efficacy of cinacalcet in secondary hyperparathyroidism (HPT) of end stage renal disease (ESRD). ERA-EDTA 2005 – European Renal Association – European Dialysis and Transplantation Association. Istanbul, Turkey, 4 – 7 June (Abstract SP210 and Poster). Nephrol. Dial. Transplant. (2005) 20(Suppl. 5):V89.
   PubMedGoogle Scholar
• MOE SM, CUNNINGHAM J, BOMMER J et al.: Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol. Dial. Transplant. (2005) 20(10):2186-2193.
   PubMed Web of Science ®Google Scholar
• CHERTOW GM, BLUMENTHAL S, TURNER S et al.: cinacalcet hydrochloride (sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium X phosphate. Clin. J. Am. Soc. Nephrol. (2006) 1(2):305-312.
   PubMedGoogle Scholar
• MESSA P, MOTELLON J, TEAM OS: Optimizing the use of cinacalcet (MimparaR/SensiparR) and Vitamin D: Results from the OPTIMA Study. American Society of Nephrology Renal Week 2005. November 8 – 13, Philadelphia, Pennsylvania (Abstract F-PO758 and Poster). J. Am. Soc. Nephrol. (2005) 16(Oct):501A.
   Google Scholar
• ISHIZUYA T, YOKOSE S, HORI M et al.: Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest. (1997) 99(12):2961-2970.
   PubMed Web of Science ®Google Scholar
• WADA M, ISHII H, FURUYA Y et al.: NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int. (1998) 53(2):448-453.
   PubMed Web of Science ®Google Scholar
• OGATA H, RITZ E, ODONI G, AMANN K, ORTH SR: Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J. Am. Soc. Nephrol. (2003) 14(4):959-967.
   PubMed Web of Science ®Google Scholar
• LOPEZ I, AGUILERA-TEJERO E, MENDOZA FJ et al.: Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J. Am. Soc. Nephrol. (2006) 17(3):795-804.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM J, DANESE M, OLSON K, KLASSEN P, CHERTOW GM: Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. (2005) 68(4):1793-1800.
   PubMed Web of Science ®Google Scholar
• MALLUCHE H, MONIER-FAUGERE M, WANG G et al.: Cinacalcet HCL reduces bone turnover and bone marrow fibrosis in hemodialysis patients with secondary hyperparathyroidism. ERA-EDTA 2004 – European Renal Association – European Dialysis and Transplantation Association. Lisbon, Portugal, 15-18 May (Abstract MO16 and Poster). Nephrol. Dial. Transplant. (2004):218b.
   Google Scholar
• FUKAGAWA M, KITAOKA M, KUROKAWA K: Resistance of the parathyroid glands to vitamin D in renal failure: implications for medical management. Kidney Int. Suppl. (1997) 62:S60-S64.
   Google Scholar
• MARTIN KJ, OLGAARD K, COBURN JW et al.: Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am. J. Kidney Dis. (2004) 43(3):558-565.
   PubMed Web of Science ®Google Scholar
• GOODMAN WG: The evolution of assays for parathyroid hormone. Semin. Dial. (2005) 18(4):296-301.
   PubMedGoogle Scholar
• SALUSKY IB, GOODMAN WG: Adynamic renal osteodystrophy: is there a problem? J. Am. Soc. Nephrol. (2001) 12(9):1978-1985.
   PubMed Web of Science ®Google Scholar
• CHARYTAN C, COBURN JW, CHONCHOL M et al.: Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am. J. Kidney Dis. (2005) 46(1):58-67.
   PubMed Web of Science ®Google Scholar
• SRINIVAS TR, SCHOLD JD, WOMER KL et al.: Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J. Am. Soc. Nephrol. (2006) 1(2):323-326.
   PubMed Web of Science ®Google Scholar
• KRUSE AE, EISENBERGER U, FREY FJ, MOHAUPT MG: The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol. Dial. Transplant. (2005) 20(7):1311-1314.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM J: Achieving therapeutic targets in the treatment of secondary hyperparathyroidism. Nephrol. Dial. Transplant. (2004) 19(Suppl. 5):V9-V14.
   Google Scholar